
Marrow Therapeutics, a biotechnology company developing genetic medicines for severe blood disorders, has launched with $173 million in combined Series A and Series B funding round.
The investment will support the development of its bone marrow-targeted therapies for diseases such as sickle cell disease and beta thalassemia.
The company raised $53 million in Series A funding, co-led by Scion Life Sciences and venBio. Its $120 million Series B round was led by OrbiMed, with participation from existing Series A investors and several new investors.
The new investors include RTW Investments, Surveyor Capital (a Citadel company), Opaleye, NEXTBio Capital, Affinity Advisors, KKR, Spruce Street Capital and Columbia Threadneedle Investments.
“We’re at a pivotal moment in genetic medicine and its application in severe blood disorders – the field has validated key targets and shown that genetic approaches can work, but we need to solve the safety and accessibility challenges to truly transform patient outcomes,” said Romesh Subramanian, Marrow Therapeutics’ President and Chief Executive Officer. “By precisely targeting the bone marrow, we’re able to deliver the potential of genetic medicines and provide sustained benefit, while simultaneously avoiding the risks that have constrained earlier approaches. Our preclinical data gives us tremendous confidence in this strategy, and we’re excited to move toward the clinic with a platform designed to address a broad range of severe hematological diseases.”
Marrow Therapeutics is developing a technology platform designed to deliver genetic medicines directly to bone marrow cells. Its proprietary Transferrin Antibody Bioconjugate (TAB) platform uses engineered antibodies to target the transferrin receptor (TfR1), helping deliver therapeutic materials to bone marrow and treat serious blood diseases.
The strategy of the company seeks to solve the issues concerning the earlier therapy with genetic medicine within the framework of safety concerns, complicated methods of manufacturing, and limited access to patients’ access.
Marrow Therapeutics is executing various projects in drug development with the help of the TAB platform. The most important development is MAR-101 that is currently under IND-enabling studies and is going to be tested for sickle cell disease (SCD) and beta thalassemia treatment.
The company has also strengthened its leadership and scientific teams. Art Levin, founding Chief Scientific Officer of Avidity Biosciences, has joined its Board of Directors. Stuart Orkin, a Harvard Medical School professor and investigator at Boston Children’s Hospital, has joined its Scientific Advisory Board.
Other key appointments include Tim Weeden as Chief Scientific Officer, John Najim as Chief Operating Officer and Chief Technology Officer and Gavriel Mullokandov as Founder and Vice President of Corporate Development. Romesh Subramanian serves as President and CEO.
With $173 million in combined funding, Marrow Therapeutics plans to advance its drug development programs and expand its bone marrow-targeted genetic medicine platform to address serious blood disorders.